Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis

References

• Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med. 2016 22;375(12):1161–1170.
   PubMed Web of Science ®Google Scholar
• Ehlken H, Schramm C. Primary sclerosing cholangitis and cholangiocarcinoma: pathogenesis and modes of diagnostics. Dig Dis. 2013;31(1):118–125.
   PubMed Web of Science ®Google Scholar
• Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis. 2006;26(1):42–51.
   PubMed Web of Science ®Google Scholar
• Folseraas T, Boberg KM. Cancer risk and surveillance in primary sclerosing cholangitis. Clin Liver Dis. 2016;20(1):79–98.
   PubMed Web of Science ®Google Scholar
• Ehlken H, Zenouzi R, Schramm C. Risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: diagnosis and surveillance. Curr Opin Gastroenterol. 2017;33(2):78–84.
   PubMed Web of Science ®Google Scholar
• Manninen P, Karvonen AL, Laukkarinen J, et al. Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease. Scand J Gastroenterol. 2015;50(4):423–428.
   PubMed Web of Science ®Google Scholar
• Morris-Stiff G, Bhati C, Olliff S, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Dig Surg. 2008;25(2):126–132.
   PubMed Web of Science ®Google Scholar
• Khuntikeo N, Pugkhem A, Titapun A, et al. Surgical management of perihilar cholangiocarcinoma: a Khon Kaen experience. J Hepatobiliary Pancreat Sci. 2014;21(8):521–524.
   PubMed Web of Science ®Google Scholar
• Nikeghbalian S, Shamsaeefar A, Eshraghian A, et al. Liver transplantation and whipple surgery combined with chemoradiotherapy for treatment of hilar cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver Transpl. 2015;21(5):696–699.
   PubMed Web of Science ®Google Scholar
• Weismüller TJ, Wedemeyer J, Kubicka S, et al. The challenges in primary sclerosing cholangitis – aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008;48(Suppl 1):S38–S57.
   PubMedGoogle Scholar
• Aljiffry M, Renfrew PD, Walsh MJ, et al. Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis. HPB (Oxford). 2011;13(2):79–90.
   PubMed Web of Science ®Google Scholar
• Gardner CS, Bashir MR, Marin D, et al. Diagnostic performance of imaging criteria for distinguishing autoimmune cholangiopathy from primary sclerosing cholangitis and bile duct malignancy. Abdom Imaging. 2015;40(8):3052–3061.
   PubMedGoogle Scholar
• Razumilava N, Gores GJ. Surveillance for cholangiocarcinoma in patients with primary sclerosing cholangitis: effective and justified? Clin Liver Dis (Hoboken). 2016;8(2):43–47.
   PubMedGoogle Scholar
• Geramizadeh B, Ghavvas R, Kazemi K, et al. Cholangiocarcinoma secondary to primary sclerosing cholangitis in explanted livers: a single-center study in the south of Iran. Hepat Mon. 2015 27;15(12):e33626.
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Facciuto M, Rubbia-Brandt L, et al., ICCA International Consortium. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology. 2016;64(4):1178–1188.
   PubMed Web of Science ®Google Scholar
• ASGE Training Committee, Jorgensen J, Kubiliun N, Law JK, et al. Endoscopic retrograde cholangiopancreatography (ERCP): core curriculum. Gastrointest Endosc. 2016;83(2):279–289.
   PubMed Web of Science ®Google Scholar
• Baron TH. Endoscopic retrograde cholangiopancreatography for cholangiocarcinoma. Clin Liver Dis. 2014;18(4):891–897.
   PubMed Web of Science ®Google Scholar
• Talukdar R. Complications of ERCP. Best Pract Res Clin Gastroenterol. 2016;30(5):793–805.
   PubMed Web of Science ®Google Scholar
• Dumonceau JM, Andriulli A, Elmunzer BJ, et al., European Society of Gastrointestinal Endoscopy. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – updated June 2014. Endoscopy. 2014;46(9):799–815.
   PubMed Web of Science ®Google Scholar
• Cotton PB. Endoscopic retrograde cholangiopancreatography: maximizing benefits and minimizing risks. Gastrointest Endosc Clin N Am. 2012;22(3):587–599.
   PubMedGoogle Scholar
• Boyd S, Tenca A, Jokelainen K, et al. Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia. Endoscopy. 2016;48(5):432–439.
   PubMed Web of Science ®Google Scholar
• Boberg KM, Jebsen P, Clausen OP, et al. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2006;45(4):568–574.
   PubMed Web of Science ®Google Scholar
• Halme L, Arola J, Numminen K, et al. Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity. Liver Int. 2012;32(5):783–789.
   PubMed Web of Science ®Google Scholar
• Moff SL, Clark DP, Maitra A, et al. Utility of bile duct brushings for the early detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Clin Gastroenterol. 2006;40(4):336–341.
   PubMed Web of Science ®Google Scholar
• Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol. 2002;37(10):1205–1211.
   PubMed Web of Science ®Google Scholar
• Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology. 2006;131(4):1064–1072.
   PubMed Web of Science ®Google Scholar
• Levy MJ, Baron TH, Clayton AC, et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol. 2008;103(5):1263–1273.
   PubMed Web of Science ®Google Scholar
• Trikudanathan G, Navaneethan U, Njei B, et al. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79(5):783–789.
   PubMed Web of Science ®Google Scholar
• Eaton JE, Gossard AA, Talwalkar JA. Recall processes for biliary cytology in primary sclerosing cholangitis. Curr Opin Gastroenterol. 2014;30(3):287–294.
   PubMed Web of Science ®Google Scholar
• Kuzu UB, Ödemiş B, Suna N, et al. The detection of cholangiocarcinoma in primary sclerosing cholangitis patients: single center experience. J Gastrointest Cancer. 2016;47(1):8–14.
   PubMedGoogle Scholar
• Ramage JK, Donaghy A, Farrant JM, et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. 1995;108(3):865–869.
   PubMed Web of Science ®Google Scholar
• Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000;95(1):204–207.
   PubMed Web of Science ®Google Scholar
• Shin SH, Lee K, Kim BH, et al. Bile-based detection of extrahepatic cholangiocarcinoma with quantitative DNA methylation markers and its high sensitivity. J Mol Diagn. 2012;14(3):256–263.
   PubMed Web of Science ®Google Scholar
• Barr Fritcher EG, Voss JS, Jenkins SM, et al. Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy. Cancer Cytopathol. 2013;121(12):708–717.
   PubMed Web of Science ®Google Scholar
• Kipp BR, Barr Fritcher EG, Pettengill JE, et al. Improving the accuracy of pancreatobiliary tract cytology with fluorescence in situ hybridization: a molecular test with proven clinical success. Cancer Cytopathol. 2013;121(11):610–619.
   PubMed Web of Science ®Google Scholar
• Bangarulingam SY, Bjornsson E, Enders F, et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology. 2010;51(1):174–180.
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Njei B, Venkatesh PG, et al. Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79(6):943–950.
   PubMed Web of Science ®Google Scholar
• Barr Fritcher EG, Kipp BR, Voss JS, et al. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol. 2011;106(11):2023–2028.
   PubMed Web of Science ®Google Scholar
• Eaton JE, Barr Fritcher EG, Gores GJ, et al. Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2015;110(2):299–309.
   PubMed Web of Science ®Google Scholar
• Barr Fritcher EG, Caudill JL, Blue JE, et al. Identification of malignant cytologic criteria in pancreatobiliary brushings with corresponding positive fluorescence in situ hybridization results. Am J Clin Pathol. 2011;136(3):442–449.
   PubMed Web of Science ®Google Scholar
• Quinn KP, Tabibian JH, Lindor KD. Clinical implications of serial versus isolated biliary fluorescence in situ hybridization (FISH) polysomy in primary sclerosing cholangitis. Scand J Gastroenterol. 2017;52(4):377–381.
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Njei B, Lourdusamy V, et al. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc. 2015;81(1):168–176.
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Hasan MK, Lourdusamy V, et al. Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review. Gastrointest Endosc. 2015;82(4):608–614.
   PubMed Web of Science ®Google Scholar
• Ramchandani M, Reddy DN, Gupta R, et al. Role of single-operator peroral cholangioscopy in the diagnosis of indeterminate biliary lesions: a single-center, prospective study. Gastrointest Endosc. 2011;74(3):511–519.
   PubMed Web of Science ®Google Scholar
• Tischendorf JJ, Kruger M, Trautwein C, et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy. 2006;38:665–669.
   PubMed Web of Science ®Google Scholar
• Meining A, Chen YK, Pleskow D, et al. Direct visualization of indeterminate pancreatobiliary strictures with probe based confocal laser endomicroscopy: a multicenter experience. Gastrointest Endosc. 2011;74:961–968.
   PubMed Web of Science ®Google Scholar
• Meining A, Shah RJ, Slivka A, et al. Classification of probe based confocal laser endomicroscopy findings in pancreaticobiliary strictures. Endoscopy. 2012;44:251–257.
   PubMed Web of Science ®Google Scholar
• Caillol F, Filoche B, Gaidhane M, et al. Refined probe-based confocal laser endomicroscopy classification for biliary strictures: the Paris classification. Dig Dis Sci. 2013;58(6):1784–1789.
   PubMed Web of Science ®Google Scholar
• Slivka A, Gan I, Jamidar P, et al. Validation of the diagnostic accuracy of probe-based confocal laser endomicroscopy for the characterization of indeterminate biliary strictures: results of a prospective multicenter international study. Gastrointest Endosc. 2015;81(2):282–290.
   PubMed Web of Science ®Google Scholar
• Heif M, Yen RD, Shah RJ. ERCP with probe-based confocal laser endomicroscopy for the evaluation of dominant biliary stenoses in primary sclerosing cholangitis patients. Dig Dis Sci. 2013;58(7):2068–2074.
   PubMed Web of Science ®Google Scholar
• Charatcharoenwitthaya P, Enders FB, Halling KC, et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. 2008;48:1106–1117.
   PubMed Web of Science ®Google Scholar
• Ringe KI, Wacker F. Radiological diagnosis in cholangiocarcinoma: application of computed tomography, magnetic resonance imaging, and positron emission tomography. Best Pract Res Clin Gastroenterol. 2015;29(2):253–265.
   PubMed Web of Science ®Google Scholar
• Zech CJ, Schoenberg SO, Reiser M, et al. Cross-sectional imaging of biliary tumors: current clinical status and future developments. Eur Radiol. 2004;14(7):1174–1187.
   PubMed Web of Science ®Google Scholar
• Kumar R, Nadig MR, Chauhan A. Positron emission tomography: clinical applications in oncology. Part 1 Expert Rev Anticancer Ther. 2005;5(6):1079–1094.
   PubMed Web of Science ®Google Scholar
• Fritscher-Ravens A, Bohuslavizki KH, Broering DC, et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun. 2001;22:1277–1285.
   PubMed Web of Science ®Google Scholar
• Sangfelt P, Sundin A, Wanders A, et al. Monitoring dominant strictures in primary sclerosing cholangitis with brush cytology and FDG-PET. J Hepatol. 2014;61(6):1352–1357.
   PubMed Web of Science ®Google Scholar
• Alkhawaldeh K, Faltten S, Biersack HJ, et al. The value of F-18 FDG PET in patients with primary sclerosing cholangitis and cholangiocarcinoma using visual and semiquantitative analysis. Clin Nucl Med. 2011;36(10):879–883.
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Njei B, Venkatesh PG, et al. Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: a systematic review and meta-analysis. Gastroenterol Rep (Oxf). 2015;3(3):209–215.
   PubMed Web of Science ®Google Scholar
• Téllez-Ávila FI, Bernal-Méndez AR, Guerrero-Vázquez CG, et al. Diagnostic yield of EUS-guided tissue acquisition as a first-line approach in patients with suspected hilar cholangiocarcinoma. Am J Gastroenterol. 2014;109(8):1294–1296.
   PubMed Web of Science ®Google Scholar
• Eloubeidi MA, Chen VK, Jhala NC, et al. Endoscopic ultrasound-guided fine needle aspiration biopsy of suspected cholangiocarcinoma. Clin Gastroenterol Hepatol. 2004;2(3):209–213.
   PubMed Web of Science ®Google Scholar
• El Chafic AH, Dewitt J, Leblanc JK, et al. Impact of preoperative endoscopic ultrasound-guided fine needle aspiration on postoperative recurrence and survival in cholangiocarcinoma patients. Endoscopy. 2013;45(11):883–889.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Sanchez W, Rosen CB, et al. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford). 2011;13(5):356–360.
   PubMed Web of Science ®Google Scholar
• Johnson KJ, Olliff JF, Olliff SP. The presence and significance of lymphadenopathy detected by CT in primary sclerosing cholangitis. Br J Radiol. 1998;71(852):1279–1282.
   PubMed Web of Science ®Google Scholar
• Hirche TO, Russler J, Braden B, et al. Sonographic detection of perihepatic lymphadenopathy is an indicator for primary sclerosing cholangitis in patients with inflammatory bowel disease. Int J Colorectal Dis. 2004;19(6):586–594.
   PubMed Web of Science ®Google Scholar
• Tsukinaga S, Imazu H, Uchiyama Y, et al. Diagnostic approach using endosonography guided fine needle aspiration for lymphadenopathy in primary sclerosing cholangitis. World J Gastroenterol. 2007 21;13(27): 3758–3759.
   PubMed Web of Science ®Google Scholar
• Arrivé L, Hodoul M, Arbache A, et al. Magnetic resonance cholangiography: current and future perspectives. Clin Res Hepatol Gastroenterol. 2015;39(6):659–664.
   PubMed Web of Science ®Google Scholar
• Cho ES, Park MS, Yu JS, et al. Biliary ductal involvement of hilar cholangiocarcinoma: multidetector computed tomography versus magnetic resonance cholangiography. J Comput Assist Tomogr. 2007;31(1):72–78.
   PubMed Web of Science ®Google Scholar
• Angulo P, Pearce DH, Johnson CD, et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol. 2000;33(4):520–527.
   PubMed Web of Science ®Google Scholar
• Rapalino O, Ratai EM. Multiparametric imaging analysis: magnetic resonance spectroscopy. Magn Reson Imaging Clin N Am. 2016;24(4):671–686.
   PubMed Web of Science ®Google Scholar
• Albiin NSI, Arnelo U, Lindberg B, et al. detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiol. 2008;49:855–862.
   PubMed Web of Science ®Google Scholar
• Jalanko H, Kuusela P, Roberts P, et al. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol. 1984;37(2):218–222.
   PubMed Web of Science ®Google Scholar
• Nichols JC, Gores GJ, LaRusso NF, et al. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc. 1993;68(9):874–879.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology. 2000;31(1):7–11.
   PubMed Web of Science ®Google Scholar
• Alvaro D, Cannizzaro R, Labianca R, et al. Cholangiocarcinoma: a position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). Dig Liver Dis. 2010;42:831–838.
   PubMedGoogle Scholar
• Schulick RD. Primary sclerosing cholangitis: detection of cancer in strictures. J Gastrointest Surg. 2008;12:420–422.
   PubMed Web of Science ®Google Scholar
• Fisher A, Theise ND, Min A, et al. CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation. Liver Transpl Surg. 1995;1:94–98.
   PubMedGoogle Scholar
• Sheen-Chen SM, Sun CK, Liu YW, et al. Extremely elevated CA 19-9 in acute cholangitis. Dig Dis Sci. 2007;52:3140–3142.
   PubMed Web of Science ®Google Scholar
• Nicholson BD, Shinkins B, Pathiraja I, et al. CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev. 2015;10(12):CD011134.
   Google Scholar
• Cheon YK, Cho YD, Moon JH, et al. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol. 2007;102(10):2164–2170.
   PubMed Web of Science ®Google Scholar
• Bonney GK, Craven RA, Prasad R, et al. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol. 2008;9(2):149-158.
   Web of Science ®Google Scholar
• Barbhuiya MA, Sahasrabuddhe NA, Pinto SM, et al. Comprehensive proteomic analysis of human bile. Proteomics. 2011;11:4443–4453.
   PubMed Web of Science ®Google Scholar
• Farina A, Dumonceau JM, Delhaye M, et al. A step further in the analysis of human bile proteome. J Proteome Res. 2011;2047–2063.
   PubMedGoogle Scholar
• Kawase HFK, Miyamoto M, Kubota KC, et al. Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues. J Proteome Res. 2009;8:4092–4103.
   PubMed Web of Science ®Google Scholar
• Kristiansen TZHH, Grønborg M, Maitra A, et al. Differential membrane proteomics using 18O-labeling to identify biomarkers for cholangiocarcinoma. J Proteome Res. 2008;11:4670–4677.
   Google Scholar
• Srisomsap C, Sawangareetrakul P, Subhasitanont P, et al. Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes. J Biomed Biotechnol. 2010;2010:437143.
   PubMedGoogle Scholar
• Lankisch TO, Metzger J, Negm AA, et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology. 2011;53(3):875-884.
   Web of Science ®Google Scholar
• Shahid G, Farid RAC, Peng J, et al. Shotgun proteomics of human bile in hilar cholangiocarcinoma. Proteomics. 2011;11(10):2134-2138.
   Web of Science ®Google Scholar
• Farina ADJ, Frossard JL, Hadengue A, et al. Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. J Proteome Res. 2009;8:159–169.
   PubMed Web of Science ®Google Scholar
• Zabron AA, H-vdS V, Wadsworth CA, et al. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease. Am J Gastroenterol. 2011;9:1711–1717.
   Google Scholar
• Arbelaiz A, Azkargorta M, Krawczyk M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2017;66(4):1125–1143.
   PubMed Web of Science ®Google Scholar
• Voigtländer T, Gupta SK, Thum S, et al. MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and/or cholangiocarcinoma. PLoS One. 2015 2;10(10):e0139305.
   PubMed Web of Science ®Google Scholar
• Bernuzzi F, Marabita F, Lleo A, et al. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clin Exp Immunol. 2016;185(1):61–71.
   PubMed Web of Science ®Google Scholar
• Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int. 2010;23(7):692–697.
   PubMed Web of Science ®Google Scholar
• Bergquist A, Glaumann H, Persson B, et al. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology. 1998;27(2):311–316.
   PubMed Web of Science ®Google Scholar
• Wu Y, Johlin FC, Rayhill SC, et al. Long-term, tumor-free survival after radiotherapy combining hepatectomy-whipple en bloc and orthotopic liver transplantation for early-stage hilar cholangiocarcinoma. Liver Transpl. 2008;14(3):279–286.
   PubMed Web of Science ®Google Scholar